Gynecological Oncology: From Pathogenesis to Therapy

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Disease Biomarker".

Deadline for manuscript submissions: 25 September 2024 | Viewed by 1028

Special Issue Editor

Special Issue Information

Dear Colleagues,

Gynecological oncology stands at the intersection of medicine, science, and compassion, and is dedicated to understanding and combating the complexities of cancers that affect the female reproductive system. From the ovaries and cervix to the uterus and beyond, this field encompasses a diverse array of malignancies, each presenting unique challenges in diagnosis, treatment, and management.

In recent decades, remarkable strides have been made in unraveling the intricate pathogenesis of gynecological cancers. Insights into the molecular underpinnings of these diseases have revolutionized our understanding, shedding light on the intricate interplay of the genetic, hormonal, and environmental factors that drive tumorigenesis. This deeper understanding has not only paved the way for earlier detection and more precise diagnostics, but has also opened avenues for targeted therapies that are tailored to individual patients, offering unprecedented hope in the face of these formidable diseases.

However, the journey from pathogenesis to therapy in gynecological oncology is a multifaceted one, and is fraught with challenges and complexities. Despite advances in research and technology, many aspects of these cancers remain enigmatic, and significant gaps persist in our knowledge, particularly concerning rare subtypes and aggressive variants that are resistant to conventional treatments.

Moreover, the landscape of gynecological oncology is continually evolving, and it is shaped by emerging trends in personalized medicine, immunotherapy, and the integration of multidisciplinary approaches. As we navigate this dynamic terrain, collaboration among clinicians, researchers, and allied healthcare professionals becomes increasingly crucial, fostering synergy in our collective efforts to improve outcomes and enhance the quality of life of those affected by gynecological cancers.

In this Special Issue, we aim to focus on gynecological oncology and explore the latest advancements in our understanding of the pathogenesis of these malignancies, the evolving landscape of diagnostic modalities, and the diverse armamentarium of therapeutic strategies at our disposal.

Dr. Stefano Cianci
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • precision medicine
  • health promotion
  • translational research
  • cancer research
  • gynecologic oncology
  • gynecologic treatment
  • gynecologic oncology pathogenesis
  • women’s health
  • cancer prevention

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

15 pages, 1852 KiB  
Systematic Review
Exploring the Relationship between Ovarian Cancer and Genital Microbiota: A Systematic Review and Meta-Analysis
by Vito Andrea Capozzi, Giosuè Giordano Incognito, Elisa Scarpelli, Marco Palumbo, Cinzia Lucia Randazzo, Alessandra Pino, Marco La Verde, Carlo Ronsini, Gaetano Riemma, Michela Gaiano, Paola Romeo, Vittorio Palmara, Roberto Berretta and Stefano Cianci
J. Pers. Med. 2024, 14(4), 351; https://doi.org/10.3390/jpm14040351 - 27 Mar 2024
Viewed by 891
Abstract
Ovarian cancer (OC) remains a significant health challenge globally, with high mortality rates despite advancements in treatment. Emerging research suggests a potential link between OC development and genital dysbiosis, implicating alterations in the microbiome composition as a contributing factor. To investigate this correlation, [...] Read more.
Ovarian cancer (OC) remains a significant health challenge globally, with high mortality rates despite advancements in treatment. Emerging research suggests a potential link between OC development and genital dysbiosis, implicating alterations in the microbiome composition as a contributing factor. To investigate this correlation, a meta-analysis was conducted following PRISMA and MOOSE guidelines, involving eight studies encompassing 3504 patients. Studies investigating the role of upper and inferior genital tract dysbiosis were included, with particular reference to HPV infection and/or history of pelvic inflammatory disease. The analysis revealed no significant difference in genital dysbiosis prevalence between OC patients and healthy controls. Although previous literature suggests associations between dysbiosis and gynecologic cancers, such as cervical and endometrial cancers, the findings regarding OC are inconclusive. Methodological variations and environmental factors may contribute to these discrepancies, underscoring the need for standardized methodologies and larger-scale studies. Despite the limitations, understanding the microbiome’s role in OC development holds promise for informing preventive and therapeutic strategies. A holistic approach to patient care, incorporating microbiome monitoring and personalized interventions, may offer insights into mitigating OC risk and improving treatment outcomes. Further research with robust methodologies is warranted to elucidate the complex interplay between dysbiosis and OC, potentially paving the way for novel preventive and therapeutic approaches. Full article
(This article belongs to the Special Issue Gynecological Oncology: From Pathogenesis to Therapy)
Show Figures

Figure 1

Back to TopTop